{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:40:14Z","timestamp":1776087614605,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"abstract":"<jats:p>\n                    AbstractPrecise diagnosis and grading of prostate cancer (PCa) are essential for determining treatment strategies and predicting patient outcomes. This study is the first to integrate\n                    <jats:sup>18<\/jats:sup>\n                    F-labeled prostate-specific membrane antigen positron emission tomography\/computed tomography (\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA PET\/CT) and multiparametric magnetic resonance imaging (mpMRI) for dual-parameter risk stratification in PCa, evaluating the noninvasive predictive value of\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA PET\/CT and mpMRI in assessing PCa risk and Ki-67 expression, and providing a novel noninvasive diagnostic approach. We analyzed 84 PCa patients who underwent\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA PET\/CT and mpMRI before or after biopsy, assessing the maximum standardized uptake value (SUV\n                    <jats:sub>max<\/jats:sub>\n                    ) from PET\/CT and minimum apparent diffusion coefficient (ADC\n                    <jats:sub>min<\/jats:sub>\n                    ) from mpMRI. PCa risk was categorized using National Comprehensive Cancer Network (NCCN) guidelines based on clinical T-staging, Gleason score, and prostate-specific antigen, while Ki-67 expression was determined immunohistochemically. High-risk patients exhibited higher SUV\n                    <jats:sub>max<\/jats:sub>\n                    , SUV\n                    <jats:sub>max<\/jats:sub>\n                    \/ADC\n                    <jats:sub>min<\/jats:sub>\n                    ratio, prostate-specific antigen, and Ki-67 positivity. The SUV\n                    <jats:sub>max<\/jats:sub>\n                    \/ADC\n                    <jats:sub>min<\/jats:sub>\n                    ratio demonstrated the strongest predictive value (area under the curve = 0.832), while ADC\n                    <jats:sub>min<\/jats:sub>\n                    best predicted Ki-67 positivity (area under the curve = 0.719). Logistic regression confirmed that SUV\n                    <jats:sub>max<\/jats:sub>\n                    , ADC\n                    <jats:sub>min<\/jats:sub>\n                    , and SUV\n                    <jats:sub>max<\/jats:sub>\n                    \/ADC\n                    <jats:sub>min<\/jats:sub>\n                    were significantly associated with PCa risk. The combined approach of\n                    <jats:sup>18<\/jats:sup>\n                    F-PSMA PET\/CT and mpMRI enhances PCa risk assessment and predicts Ki-67 expression, indicating potential for disease progression and metastasis. SUV\n                    <jats:sub>max<\/jats:sub>\n                    \/ADC\n                    <jats:sub>min<\/jats:sub>\n                    is a key imaging parameter for evaluating tumor biology and may guide treatment strategies.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046160","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:01:09Z","timestamp":1764597669000},"page":"e46160","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["18F-PSMA PET\/CT and mpMRI: A combined approach for enhanced risk stratification in prostate cancer\u2014a diagnostic accuracy study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4724-095X","authenticated-orcid":false,"given":"Mierzhayiti","family":"Aihemaitijiang","sequence":"first","affiliation":[{"name":"Department of Urology Surgery Center, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiology, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangli","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Center, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School of Xinjiang Medical University, Urumqi, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikebaier","family":"Wumaner","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Center, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Center, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanwei","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Center, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0260-3097","authenticated-orcid":false,"given":"Zhenfeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery Center, People\u2019s Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260121","first-page":"363","article-title":"Cancer treatment and survivorship statistics.","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R2-20260121","first-page":"1288","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 1.2023.","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Nat Comprehensive Cancer Netw"},{"key":"R3-20260121","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00259-014-2915-3","article-title":"[(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice.","volume":"42","author":"Krohn","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260121","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis.","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R5-20260121","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet (London, England)"},{"key":"R6-20260121","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.euf.2020.09.015","article-title":"Potential candidates for focal therapy in prostate cancer in the era of magnetic resonance imaging-targeted biopsy: a large multicenter cohort study.","volume":"7","author":"von Hardenberg","year":"2021","journal-title":"Eur Urol Focus"},{"key":"R7-20260121","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jmri.27895","article-title":"Prostate cancer diffusion-weighted magnetic resonance imaging: does the choice of diffusion-weighting level matter?","volume":"55","author":"Maier","year":"2022","journal-title":"J Magn Resonance Imag"},{"key":"R8-20260121","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology.","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Comprehensive Cancer Netw"},{"key":"R9-20260121","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/bjc.2012.598","article-title":"Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.","volume":"108","author":"Fisher","year":"2013","journal-title":"Br J Cancer"},{"key":"R10-20260121","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00330-020-07191-z","article-title":"Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.","volume":"31","author":"Dunet","year":"2021","journal-title":"Eur Radiol"},{"key":"R11-20260121","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1007\/s00330-016-4284-8","article-title":"Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma.","volume":"26","author":"Preda","year":"2016","journal-title":"Eur Radiol"},{"key":"R12-20260121","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/s12885-022-10037-0","article-title":"Diagnostic value of integrated 18F-FDG PET\/MRI for staging of endometrial carcinoma: comparison with PET\/CT.","volume":"22","author":"Yu","year":"2022","journal-title":"BMC Cancer"},{"key":"R13-20260121","doi-asserted-by":"crossref","first-page":"17949","DOI":"10.1038\/s41598-023-45158-4","article-title":"Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer.","volume":"13","author":"B\u00f8rretzen","year":"2023","journal-title":"Sci Rep"},{"key":"R14-20260121","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.urolonc.2017.05.004","article-title":"Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis.","volume":"35","author":"Berlin","year":"2017","journal-title":"Urol Oncol"},{"key":"R15-20260121","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/JU.0000000000002120","article-title":"Systematic versus targeted magnetic resonance imaging\/ultrasound fusion prostate biopsy among men with visible lesions.","volume":"207","author":"Patel","year":"2022","journal-title":"J Urol"},{"key":"R16-20260121","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging.","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"key":"R17-20260121","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer.","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"R18-20260121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4274\/mirt.galenos.2019.63825","article-title":"Correlation of SUVmax and apparent diffusion coefficient values detected by Ga-68 PSMA PET\/MRI in primary prostate lesions and their significance in lymph node metastasis: preliminary results of an on-going study.","volume":"28","author":"Uslu-Be\u015fli","year":"2019","journal-title":"Mol Imag Radionuclide Ther"},{"key":"R19-20260121","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/RLU.0000000000001991","article-title":"SPECT\/CT With the PSMA Ligand 99mTc-MIP-1404 for whole-body primary staging of patients with prostate cancer.","volume":"43","author":"Schmidkonz","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R20-20260121","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12149-014-0825-x","article-title":"Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET\/MRI: combined SUV and ADC analysis.","volume":"28","author":"Wetter","year":"2014","journal-title":"Ann Nucl Med"},{"key":"R21-20260121","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2214\/AJR.13.11304","article-title":"Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET\/MRI.","volume":"201","author":"Rakheja","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"R22-20260121","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1097\/RLU.0000000000002289","article-title":"68Ga-PSMA-11 PET\/CT in newly diagnosed prostate adenocarcinoma.","volume":"43","author":"Erg\u00fcl","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R23-20260121","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2214\/AJR.18.19585","article-title":"Improving diagnosis of primary prostate cancer with combined 68Ga-Prostate-specific membrane antigen-HBED-CC Simultaneous PET and multiparametric MRI and clinical parameters.","volume":"211","author":"Jena","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"R24-20260121","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3889\/oamjms.2018.309","article-title":"Assessment of expression of Ki-67 in benign and malignant prostatic lesions among sudanese patients.","volume":"6","author":"Mohamed","year":"2018","journal-title":"Open Access Macedonian J Med Sci"},{"key":"R25-20260121","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.acra.2013.09.007","article-title":"Diffusion-weighted imaging of prostate cancer on 3T MR: relationship between apparent diffusion coefficient values and Ki-67 expression.","volume":"20","author":"Zhang","year":"2013","journal-title":"Acad Radiol"},{"key":"R26-20260121","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1515\/raon-2016-0033","article-title":"The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients.","volume":"50","author":"Pascale","year":"2016","journal-title":"Radiol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:02:05Z","timestamp":1768993325000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":26,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046160","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-02-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}